Navigation Links
Bioartificial Kidney Cuts Death Risk, Improves Outcomes
Date:4/30/2008

In small study, device helped a little more than half of patients recover renal function

WEDNESDAY, April 30 (HealthDay News) -- Another successful clinical trial suggests that a bioartificial kidney to save the lives of people with acute renal failure will be available within a few years.

This latest study found that short-term replacement of renal cell function using the renal tubule assist device (RAD) -- the living cartridge that's critical to the function of the bioartificial kidney -- significantly reduced death risk and sped recovery of kidney function in patients with acute renal failure resulting from acute kidney injury.

The study of 58 critically ill patients, aged 18 to 80, found that the death rate after 28 days was 33 percent for patients who received continuous venovenous hemofiltration combined with RAD, compared to 66 percent for patients who received the more traditional continuous renal replacement therapy. At day 28, 53 percent of the patients in the RAD group had recovered renal function.

In the 180 days following treatment, patients in the RAD group had a 50 percent reduction in death risk. The study was published online in the Journal of the American Society of Nephrology.

"Our study results are encouraging, and they raise expectations that our new approach may yield a better treatment for life-threatening acute renal failure, for which a high mortality rate has remained unchanged [50 percent to 70 percent] despite years of advances in conventional therapies," study author Dr. H. David Humes, a professor of internal medicine at the University of Michigan School of Medicine, said in a prepared statement.

"Even more promising, the nature of our new approach -- using living cells as therapeutic agents -- argues for the feasibility of developing whole classes of new cell-based and tissue-engineered therapies," Humes said.

While this was a small study, he said it offers encouragement that a related device -- a wearable kidney that performs natural functions -- can be developed in the near future to treat people with chronic renal failure.

"The ability to harness vital processes of cells, to target their living molecular machinery on restoring critical substances which have become disordered by disease, has vast implications for the future of medicine," Humes said. "The apparently successful use of living cells in this way validates our approach and should encourage others to investigate cell therapies for a range of disorders."

He and his colleagues started developing the bioartificial kidney more than a decade ago. The device includes a cartridge that filters the blood as in traditional kidney dialysis. The cartridge is connected to the RAD, which is made of hollow fibers lined with a type of kidney cell called renal proximal tubule cells, which reclaim vital electrolytes, salt, glucose and water, and control production of immune system molecules called cytokines, which fight infection.

More information

The American Academy of Family Physicians has more about kidney failure.



-- Robert Preidt



SOURCE: University of Michigan Health System, news release, April 24, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Kidney Care Community Applauds National Taxpayers Unions Endorsement of Medicare Reforms to Extend Patient Private Health Insurance Coverage; Calls Proposal Common Sense Coverage Reform
2. Cutting Phosphate May Protect Kidney Patients From Heart Trouble
3. Muscle Mass May Not Explain High Creatinine in Black Kidney Patients
4. Readily available treatment could help prevent heart disease in kidney patients
5. Study Points to New Treatments for Polycystic Kidney Disease
6. Raloxifene Safe for Women With Decreased Kidney Function
7. Kidney cancer deaths show overall decrease in Europe
8. Diplomat Specialty Pharmacy Hires National Accounts Director To Expand Kidney Disease Services
9. Northwestern Memorial Successfully Completes Rare Four-Way Domino Paired Kidney Exchange Transplant Surgery
10. Kidney Community Gathers on Capitol Hill to Ask Congress to Support Legislation for Increased Kidney Care Education, Updates for Kidney Dialysis Benefit
11. Hospital Clínic conducts the first kidney extraction through the vagina in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... Salucro, the ... the health care industry’s hospitals and provider groups, has announced that it will ... customers. Parasail Health is a San Francisco health-finance startup that has launched a ...
(Date:6/27/2017)... NY (PRWEB) , ... June 27, 2017 , ... From ... members. The three-day event was held in Syracuse, New York, where EarQ is headquartered. ... changing industry, how to connect with today’s savvy consumer, and the latest in ...
(Date:6/27/2017)... ... June 27, 2017 , ... The Kelahan Agency, ... services to residents of southern New Hampshire, is teaming up with the New ... hunger and homelessness in the region. , New Horizons for New Hampshire provides ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Scholarship Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and maintenance ... their experience in these popular periodontal procedures. Drs. Toback and Urbanski practice as ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Today, June ... suffer from PTSD. Yet less than 20% will receive adequate care due to lack ... PTSD won't receive any care at all. And left untreated, veterans are at an ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)...  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. ... Iowa location. The Iowa ... an ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition ... of pollutants. "Our new cleanroom ... serve our Iowa patients," said Phil ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
(Date:5/30/2017)... , May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... data solutions, today announced that it will be presenting at the ... 8:00 AM PT. Erez Raphael , CEO, of DarioHealth will ... conference will be held on June 6th & 7th, 2017 at ... in the small / micro-cap space. ...
Breaking Medicine Technology: